Ractigen Therapeutics to Present First-in-Human RNA Activation Data in Duchenne Muscular Dystrophy as a Late-Breaking Oral Presentation at the 31st Annual Congress of the World Muscle Society

A late-breaking presentation at the 31st Annual World Muscle Society Congress is expected to provide what the company describes as the first clinical evidence for a small activating RNA (saRNA). The late-breaking designation indicates the program committee views the findings as immediately important to the neuromuscular disease field, although the article excerpt provides no clinical efficacy, safety, or financial data.